about
Anaplastic oligodendrogliomas with 1p19q codeletion have a proneural gene expression profileTemozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial.Autoimmune episodic ataxia in patients with anti-CASPR2 antibody-associated encephalitis[Limbic encephalitis. A misdiagnosed syndrome].Mitotic index, microvascular proliferation, and necrosis define 3 groups of 1p/19q codeleted anaplastic oligodendrogliomas associated with different genomic alterations.An ANOCEF genomic and transcriptomic microarray study of the response to radiotherapy or to alkylating first-line chemotherapy in glioblastoma patients.SNP array analysis reveals novel genomic abnormalities including copy neutral loss of heterozygosity in anaplastic oligodendrogliomas.Methylation profiling identifies 2 groups of gliomas according to their tumorigenesisProlonged response without prolonged chemotherapy: a lesson from PCV chemotherapy in low-grade gliomasGenomic changes in progression of low-grade gliomas.Peri-ictal pseudoprogression in patients with brain tumor.Increasing the Time Interval between PCV Chemotherapy Cycles as a Strategy to Improve Duration of Response in Low-Grade Gliomas: Results from a Model-Based Clinical Trial Simulation.Characteristics of gliomas in patients with somatic IDH mosaicism.Integrated multi-omics analysis of oligodendroglial tumours identifies three subgroups of 1p/19q co-deleted gliomas.Molecular genetic markers as predictors of response to chemotherapy in gliomas.Prognostic value of health-related quality of life for death risk stratification in patients with unresectable glioblastoma.Neuroleptic intolerance in patients with anti-NMDAR encephalitis.Therapeutic application of noncytotoxic molecular targeted therapy in gliomas: growth factor receptors and angiogenesis inhibitors.Diagnostic and prognostic markers in gliomas.Validation of the high-performance of pyrosequencing for clinical MGMT testing on a cohort of glioblastoma patients from a prospective dedicated multicentric trial.Contrast enhancement in 1p/19q-codeleted anaplastic oligodendrogliomas is associated with 9p loss, genomic instability, and angiogenic gene expression.Prognostic markers in gliomas.Predictive and prognostic factors for gliomas.Quantitative morphological magnetic resonance imaging follow-up of low-grade glioma: a plea for systematic measurement of growth rates.Chemotherapy in low-grade gliomas.Predictive biomarkers in adult gliomas: the present and the future.Treating glioblastoma patients with poor performance status: where do we go from here?Anti-NMDA-R encephalitis: Should we consider extreme delta brush as electrical status epilepticus?CIC inactivating mutations identify aggressive subset of 1p19q codeleted gliomas.Prognostic impact of the 2016 WHO classification of diffuse gliomas in the French POLA cohort.Oncological patterns of care and outcomes for 265 elderly patients with newly diagnosed glioblastoma in France.Autoimmune limbic encephalopathy and anti-Hu antibodies in children without cancer.Cortical and subventricular zone glioblastoma-derived stem-like cells display different molecular profiles and differential in vitro and in vivo properties.A tumor growth inhibition model for low-grade glioma treated with chemotherapy or radiotherapy.New targeted therapies in pituitary carcinoma resistant to temozolomide.Anaplastic gliomas in adults: an update.Autoimmune N-methyl-D-aspartate receptor encephalitis is a differential diagnosis of infectious encephalitis.Postradiation lumbosacral radiculopathy with spinal root cavernomas mimicking carcinomatous meningitis.Alpha-internexin expression predicts outcome in anaplastic oligodendroglial tumors and may positively impact the efficacy of chemotherapy: European organization for research and treatment of cancer trial 26951.Devic's syndrome-like phenotype associated with thymoma and anti-CV2/CRMP5 antibodies.
P50
Q21245722-B7D984D0-6A21-4B5D-A8B7-CCBAC1496586Q33395957-B8248051-053A-420D-9292-1D07DA1767B5Q33800529-BED5F5D0-5889-4C07-B317-812ED02DA403Q34013748-ADD44618-FF7B-4A37-831B-6EA45566F84DQ34062043-D665B4A2-B2CC-4F97-B983-72834052F9BDQ34149065-5ED6B0D9-DFC1-4683-A145-66E626943AF5Q34446905-5A94F218-7258-4AF9-A6EE-A08ECBA32399Q34480513-A8C6D432-EA45-4D60-AFBF-6DF421E83562Q34480589-7EE8AE0F-4F9A-4568-9439-9922A50C70D9Q34794665-226B86C9-67E6-4E44-8B5C-AA5FF834D3B6Q35085349-CC316357-5C27-4B0F-A4E3-D67593F53828Q36409030-64B6AC7F-D3EF-45C2-A6BD-8F1940B58864Q36758670-78291D96-8D94-4E64-87E9-2DEF0B3B658CQ36819744-AA87CCD3-EE67-42BF-8688-842FF895CA65Q36956110-23293168-DB96-4C4C-ACA5-E197A22E7644Q36969519-B84EB3AD-69FB-4F38-99FE-688FE6979E3CQ37216597-46F2D253-0CEA-4467-9DC8-18A2B5F76F44Q37263782-DBD738EE-EC40-4C84-8F90-B1B42CABF76CQ37577244-13724506-7AD0-46E3-8169-5B3594053616Q37641708-FFEA3CD2-299B-4A38-8029-C5ECDA0C2421Q37699417-DBB527AD-95E9-46A0-8C6D-2DBC3DF75428Q37750781-2E4604AF-4AB9-413E-95ED-15A930E3FA3BQ37873473-710F35FF-262B-4F06-BC9B-6D20614BDCB5Q38016287-7F195C9A-FDD9-4AA3-9696-9F045782F93DQ38036802-FDF2BE11-D349-49CE-A0ED-88E0BD0CACBAQ38146515-DCD74829-9B23-4168-8A5C-6FC4A34E6378Q38233183-A81AA858-5D80-473E-BB3B-B62755380373Q38753009-8FC9EC42-FF68-42F2-9BFD-A1317738802CQ38870277-090AD5F5-64D0-468B-AD30-C7471D2D5CA2Q38940482-B292B2E0-5949-4DE1-90EF-1FC03C5D9009Q39250933-FDABDB16-968B-422C-90C1-004D80664489Q39422118-2FE74F93-281C-4F81-905E-63DB046B0CB0Q39459834-3B10CF0A-0D82-4108-8651-9BAADC8C8EADQ39591885-F6556F8F-3381-4A2E-B828-9E1F40BB06DAQ39715502-3E48CA89-63FB-48F8-BB4F-1A2203F835F0Q40043903-6EBBBAF7-0066-435F-B791-39B86A77A7D8Q42236139-2A4FE79D-1A19-46BD-A022-56FA7CA16BE7Q42661309-6A0A4FB8-B600-4D59-88D0-7AB73F568BABQ42756714-CEC1CE9D-70B3-4A8C-BA85-DC05B8277CD6Q42765625-A2EF5901-914A-4583-9C34-542A1B37DAF2
P50
name
François Ducray
@ast
François Ducray
@en
François Ducray
@nl
type
label
François Ducray
@ast
François Ducray
@en
François Ducray
@nl
prefLabel
François Ducray
@ast
François Ducray
@en
François Ducray
@nl